Cash Flows: Net financing inflow of $10.78 million for the nine months ended September 30, 2025 (capital raises of $5.87 ...

Revenue: $3.83 million for third quarter 2025 (down 13.9% YoY from $4.45 million), and $11.59 million for the nine months ended September 30, 2025 (down 15.4% YoY from $13.69 million), reflecting a ...

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, New Age ...

Chairman Powell's term ends in May, and speculators currently see the most likely replacement is one of two Kevins. Odds ...

With that in mind, here are two ASX giants that I believe have the qualities required to still be thriving and potentially ...

In spite of soaring revenue, losses at OpenAI ballooned. The company OpenAI reportedly expects to burn through $9 billion in ...

However, a strong argument can be made that these well-known catalysts, while foundational in supporting the multi-year ...

Boston Scientific is a Buy with a $109 target and 14% upside from strong demand, Q3 beats, raised FY25 guidance, and growth ...

I'm going to be honest, I was underwhelmed by Gemini's response. This is exactly why investors shouldn't turn to AI for investing guidance. The post I asked Gemini for the perfect passive income ...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the ...

IPP 2024 Revenue Guidance -- $24 million to $26 million, with segment gross margin anticipated at approximately 50%. DSA 2024 Revenue Guidance -- Expected to exceed $20 million. EBITDA Forecast -- ...

Last year’s stock ideas from MoneyWeek’s columnist and trader, Michael Taylor, produced another strong performance. This year ...